Gimenez: Decentralized biotech enables curing long-tail rare diseases centralized systems ignore
Dr. Francisco Gimenez · The Year That Changed Medicine Forever | Francisco Gimenez Explains the Biotech Revolution. · Joe Lonsdale · Apr 18, 2022 · at 39:26
Dr. Francisco Gimenez, partner at 8VC, draws an analogy between retail marketplaces and biotechnology while discussing decentralized healthcare innovation with Joe Lonsdale.
0:00 / 0:32exact quote · 32.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“If you think about that same model of like this long tail, it can be profitable if you think at a global scale, and we actually reduce the cost to actually start these kinds of innovations and distribute them to people. And think about that in the context of diseases rather than SKUs, right? There are, you know, Hundreds of thousands, if not millions of rare diseases that if we can think about this on a global scale to cure them and allow smaller entities to cure them more quickly and cheaply, then we can actually start hitting this long tail that doesn't make sense in these centralized systems.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Francisco Gimenez
Gimenez: More biotechs will commercialize drugs independently instead of selling
“I would say my sort of falsifiable prediction would be that we're going to start seeing more and more biotechs make drugs that they try to commercialize themselves as opposed to selling to pharma to do the commercialization.”
Gimenez: Rare cancer therapies build infrastructure to cure broader diseases
“Once we create the tools and technologies to cure those,
We have this infrastructure layer that allows us to expand it to so many others. So we cure rare cancers or cell therapies today, but we're looking and building all of the infrastructure, the manufactur…”
Gimenez: Eliminating Startup Upside Would Entrench Incumbent Pharma
“If we didn't give people upside to translate these things, there would not be a system to actually sort of commercialize these things in a sort of fast turnaround biotech ecosystem. We would be dependent, it's not like that, that innovation would go away, but …”
Gimenez: Just 100 to 200 pharma CSOs dictate which diseases get cured
“So we've got, like, on the order of, what, a hundred, maybe 200 pharmas looking to make these M&As. So it means a hundred to 200 chief scientific officers are dictating what does.”
Gimenez: Tenured academics enjoy the privilege of principle without practical trade-offs
“If you are in a tenured position in academia and you consider moving to industry, the dark side, which is always considered like the phrase that they tell you have like the privilege of principle that many other people don't, right? You don't have to make trad…”
Gimenez: Life sciences will shift from curing diseases to active human enhancement
“I think we would flip the model of what we think of in bio life sciences from amelioration of suffering, which is essentially curing diseases, to sort of improvement of, like, human condition, like this, the transhumanist might call it something like that”